On April 30, the Centers for Medicare and Medicaid Services (CMS) released a second Interim Final Rule and additional waivers that provide increased regulatory relief and flexibility for healthcare providers during the public health emergency. Through this rulemaking, CMS delayed the implementation of the Qualified Clinical Data Registry (QCDR) measure testing and data collection approval criteria by 1 year.
In consideration of clinicians’ limited resources and to reduce burden on clinicians and healthcare organizations that are responding to the COVID-19 pandemic, CMS is delaying the timeline for the QCDR measure approval criteria previously finalized in the CY 2020 Medicare Physician Final Fee Schedule.
- Measure Testing: The QCDR measure testing approval criteria requires data to be collected from clinicians on each measure prior to the QCDR’s self-nomination application. CMS is delaying this requirement until the 2022 performance period.
- Data Collection: QCDRs are required to collect data on a QCDR measure, appropriate to the measure type, before submitting the QCDR measure for CMS consideration during the self-nomination period. CMS is delaying this requirement until the 2022 performance period.
Additional information about QCDRs can be found on this CMS guide and additional information about the current flexibilities for the Quality Payment Program can be found on this COVID-19 resource guide.
For more information visit the McDermottPlus Payment Innovation Resource Center or contact Sheila Madhani at 202-204-1459 or email@example.com.